MedTrace Logo

A Phase I Study to Assess the Safety and Distribution of VB-111 in Patients With Advanced Metastatic Cancer

NCT00559117 · Status: UNKNOWN · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 48

Last updated 2015-03-27

No results posted yet for this study

Summary

Aim of the study is to evaluate the safety and find the maximal tolerated dose of VB-111 in Patients with Advanced Metastatic Cancer

Conditions

  • Advanced and/or Metastatic Solid Organ Cancer

Interventions

DRUG

VB-111

A single intravenously infusion of diluted VB-111 should be administered 1 ml/minute

Sponsors & Collaborators

  • Vascular Biogenics Ltd. operating as VBL Therapeutics

    lead INDUSTRY

Principal Investigators

  • Pierre Triozzi, Dr. · The Cleveland Clinic

  • Andrew Brenner, MD · UTHSC- CTRC and Institute for Drug Development

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2007-11-30
Primary Completion
2015-06-30
Completion
2015-06-30

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00559117 on ClinicalTrials.gov